
Could adaptive therapy improve PARPi maintenance for ovarian cancer? I’m very happy and proud to share our new paper, now out in Cell Systems: cell.com/cell-systems/fullte… A tweetorial [1/12]

Eric and Wendy Schmidt AI in Science Postdoctoral Fellow. Combining ecology, evolution and mathematics to improve cancer treatment scheduling.

Could adaptive therapy improve PARPi maintenance for ovarian cancer? I’m very happy and proud to share our new paper, now out in Cell Systems: cell.com/cell-systems/fullte… A tweetorial [1/12]


Excited to begin a new chapter as an Eric and Wendy Schmidt AI in Science Postdoctoral Fellow at @imperialcollege & @ICR_London! I’ll be combining math modeling and AI to optimize cancer treatment. Ping me if you're interested in #MathOnco, #CancerEvolution, or reducing toxicity!

It has been an amazing experience working with #TeamRuby. And thanks to the leadership and energy of @ErinGeorgeMD experiments exploring new targeted therapy combos have already started. Can’t wait to see where this goes next! @MoffittNews @mathonco

To read more: biorxiv.org/content/10.1101/…

Idea 3: strategies to mitigate chemotherapy-induced microbiome damage to empower adjuvant immunotherapy.

Idea 2: low dose targeted therapy combos, optimized via math models, to provide options for those patients who are not eligible for PARPis.

Idea 1: Better toxicity monitoring systems using AI and new fluctuating methylation clocks to assess bone marrow health.

Evolutionary theory tells us that to cure #ovariancancer we need to target it when its most vulnerable – at the end of 1st-line tx. The challenge: that’s also when treatment-induced toxicity is greatest. Check out our new @imoworkshop pre-print with 3 ideas how to tackle this!

Save the date #MathOnco25! October 29th-31st in Tampa, Florida. Directly before the 13th @imoworkshop (November 3rd-7th) - stay the weekend and brainstorm the beaches! More information to follow but @EvolTherapy will be a key theme @mathonco @MoffittNews

Attention #MathOnco friends! We'd like to put together a collage of pictures of the mathonco presence at #AACR25 for the @mathoncoblog newsletter. DM me yours by Monday (05/05) if you'd like to see yours included.

Very proud of this team snatching up 1st place & $50k pilot funding towards beating HR+ #ovariancancer at @imoworkshop. It was my 1st time as team lead and more than anything it was simply a lot of fun! Thanks #TeamRuby for an incredible week! Looking forward to what's next!
The winners of the 12th @imoworkshop on Toxicity are #TeamRed! Led by the synergistic combination of @ErinGeorgeMD @StroblMAR & Paulo Rodriguez. Congratulations on a unanimous win!! Excited to see where this project goes with the $50K winning prize from @MoffittNews #MoffittIMO

Thanks for the shoutout! I fully agree. Models help us to better design and interpret our experiments and conversely experiments enable us to calibrate and advance our models. In short: Integration drives iteration drives progress!
#SysBio4CancerResearch: The best way to bring preclinical data to bear on clinical translation is the integration of mathematical models to interpolate or extrapolate these data, and to test & generate hypotheses about underlying biological mechanisms. A recent great example of model iteration is @stroblmar’s paper on PARP inhibitors in ovarian cancer: cell.com/cell-systems/abstra…

#SysBio4CancerResearch: The best way to bring preclinical data to bear on clinical translation is the integration of mathematical models to interpolate or extrapolate these data, and to test & generate hypotheses about underlying biological mechanisms. A recent great example of model iteration is @stroblmar’s paper on PARP inhibitors in ovarian cancer: cell.com/cell-systems/abstra…

Our recent @PRX_Life paper was selected as the very first journal cover and it looks great :) Past thread explaining why we're are just so excited about this result below:
Incredibly excited that our paper examining the role of ecological interactions in preexisting drug resistance is out! We tackle the apparent paradox between the cost of resistance in the absence of treatment, and the ubiquity of preexistence. 1/20 Link: go.aps.org/4c5FmH4
